FDA approves heart laser treatmentBMJ 1998; 316 doi: https://doi.org/10.1136/bmj.316.7142.1407e (Published 09 May 1998) Cite this as: BMJ 1998;316:1407
- Deborah Josefson
- San Francisco
A laser treatment for refractory angina known as transmyocardial revascularisation has won cautious approval from a Food and Drug Administration advisory panel. Last year the technique was rejected.
The treatment is an experimental procedure in which 2040 holes, each 1 mm in diameter, are drilled by a laser into a beating left ventricle. PLC Systems, the manufacturer of the laser, had applied for FDA approval of its heart laser system and of the technique.
Proponents of the procedure believe that the holes promote angiogenesis and mature into blood vessels, which subsequently feed oxygen rich blood to ischaemic myocardium. But little evidence exists that this …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial